Humans487 adult smokers3 monthsCohort study

Patient-Level Determinants Outweigh Pharmacotherapy Choice in Smoking Cessation: Evidence from a Real-World Study in Turkey

Figure 1. STROBE flow diagram of participant recruitment, non-randomized treatment allocation, loss to follow-up, and final analysis at the 3-month endpoint.
Open the figure at full size
Figure 1. STROBE flow diagram of participant recruitment, non-randomized treatment allocation, loss to follow-up, and final analysis at the 3-month endpoint.STROBE flow diagram of participant recruitment, non-randomized treatment allocation, loss to follow-up, and final analysis at the 3-month endpoint.Mutlu et al. · CC BY

Healthcare

Abstract

Background/Objectives: The relative contribution of pharmacotherapy versus patient-level factors to smoking cessation success remains unclear, particularly in real-world settings where access to first-line treatments such as varenicline is limited.

The paper

Sağlık Bilimleri Üniversitesi

Healthcare · 19 Sep 2026 · CC BY

doi.org/10.3390/healthcare14183090PubMed 42793628